| (Values in U.S. Thousands) | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 80 | -20 | -30 | -20 |
| Net Income Growth | -100.00% | +500.02% | +33.33% | -50.00% | unch |
Verisante Technology Inc (VRSEF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Verisante Technology, Inc. operates as a medical device company engaged in the development of innovative systems for the early detection of cancer. It develops and offers a range of compact, non'invasive cancer detection devices for many of the most common cancers, including gastro'intestinal, colorectal and cervical cancers. The Company's Verisante Aura series is a novel multimodality imaging and spectroscopy system designed to aid in the early detection of skin cancer. Other product offered by the company includes Verisante Core series and Authenticare- a pre-production prototype of a pharmaceutical tablet analyzer for the authentication of solid dosage pharmaceuticals. Verisante Technology, Inc. is based in Vancouver, British Columbia.
Fiscal Year End Date: 12/31